UY29822A1 - "4-(4-bromo-2-fluoroanilino)-6-metoxi-7-(1-metilpiperidin-4-ilmetoxi)quinazolina como monohidrato, composiciones farmacéuticas conteniéndolos y proceso de preparación - Google Patents

"4-(4-bromo-2-fluoroanilino)-6-metoxi-7-(1-metilpiperidin-4-ilmetoxi)quinazolina como monohidrato, composiciones farmacéuticas conteniéndolos y proceso de preparación

Info

Publication number
UY29822A1
UY29822A1 UY29822A UY29822A UY29822A1 UY 29822 A1 UY29822 A1 UY 29822A1 UY 29822 A UY29822 A UY 29822A UY 29822 A UY29822 A UY 29822A UY 29822 A1 UY29822 A1 UY 29822A1
Authority
UY
Uruguay
Prior art keywords
monohydrate
methylipiperidin
ilmetoxi
metoxi
fluoroanilino
Prior art date
Application number
UY29822A
Other languages
English (en)
Inventor
Richard Anthony Storey
Rebecca Jane Booth
Zakariya Patel
Brian Roger Meyrick
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29822(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29822A1 publication Critical patent/UY29822A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

- monohidrato de 4-(4-BROMO-2-FLUOROANILINO)-6-METOXI-7-(1-METILPIPERIDIN-4-ILMETOXI)QUINAZOLINA - procedimientos de preparación de dicho monohidrato - composiciones farmacéuticas donde dicho monohidrato es el ingrediente activo, - uso de dicho monohidrato para fabricación de medicamentos para su utilización como antiangiogénicos y/o reductores de la permeabilidad vascular (contra el cáncer) en animales de sangre caliente tales como seres humanos, - uso de dicho monohidrato en tratamiento de estados de enfermedad vinculados con la angiogénesis y/o el aumento de la permeabilidad vascular, tal como el cáncer, en animales de sangre caliente tales como seres humanos.
UY29822A 2005-09-30 2006-09-29 "4-(4-bromo-2-fluoroanilino)-6-metoxi-7-(1-metilpiperidin-4-ilmetoxi)quinazolina como monohidrato, composiciones farmacéuticas conteniéndolos y proceso de preparación UY29822A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0519878.3A GB0519878D0 (en) 2005-09-30 2005-09-30 Chemical compound

Publications (1)

Publication Number Publication Date
UY29822A1 true UY29822A1 (es) 2007-04-30

Family

ID=35395000

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29822A UY29822A1 (es) 2005-09-30 2006-09-29 "4-(4-bromo-2-fluoroanilino)-6-metoxi-7-(1-metilpiperidin-4-ilmetoxi)quinazolina como monohidrato, composiciones farmacéuticas conteniéndolos y proceso de preparación

Country Status (16)

Country Link
US (1) US20080312261A1 (es)
EP (1) EP1937665A1 (es)
JP (1) JP2009510040A (es)
KR (1) KR20080059276A (es)
CN (1) CN101277947A (es)
AR (1) AR056557A1 (es)
AU (1) AU2006296371A1 (es)
BR (1) BRPI0616583A2 (es)
CA (1) CA2623646A1 (es)
GB (1) GB0519878D0 (es)
IL (1) IL190010A0 (es)
NO (1) NO20081266L (es)
TW (1) TW200745083A (es)
UY (1) UY29822A1 (es)
WO (1) WO2007036717A1 (es)
ZA (1) ZA200802640B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
AU769222B2 (en) * 1999-11-05 2004-01-22 Genzyme Corporation Quinazoline derivatives as VEGF inhibitors

Also Published As

Publication number Publication date
ZA200802640B (en) 2010-09-29
TW200745083A (en) 2007-12-16
IL190010A0 (en) 2008-08-07
AR056557A1 (es) 2007-10-10
GB0519878D0 (en) 2005-11-09
EP1937665A1 (en) 2008-07-02
JP2009510040A (ja) 2009-03-12
AU2006296371A1 (en) 2007-04-05
CN101277947A (zh) 2008-10-01
US20080312261A1 (en) 2008-12-18
CA2623646A1 (en) 2007-04-05
KR20080059276A (ko) 2008-06-26
NO20081266L (no) 2008-06-27
BRPI0616583A2 (pt) 2011-06-21
WO2007036717A8 (en) 2008-03-27
WO2007036717A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
UY28702A1 (es) Derivados de quinazolina
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
MX2007008924A (es) Compuestos quimicos.
TW200634003A (en) Chemical compounds
TW200716623A (en) Chemical compounds
TW200616974A (en) Chemical compounds
TW200736234A (en) Chemical compounds
TW200621730A (en) Chemical compounds
TW200621259A (en) Chemical compounds
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
RU2010123052A (ru) Авенантрамидсодержащие композиции
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
MX2010007523A (es) Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer.
BRPI0914902B8 (pt) Composição farmacêutica para uso no tratamento de mal de parkinson
PL2210588T3 (pl) Kompozycje pianotwórcze do leczenia skóry ludzkiej zasadniczo niezawierające aktywnych składników farmaceutycznych
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
BR112014028813A2 (pt) 5-amino[1,4]tiazinas como inibidores bace1
PT1893237E (pt) Composição farmacêutica compreendendo um elastómero organopolissiloxano e um princípio activo solubilizado
WO2009057139A3 (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
UY29822A1 (es) "4-(4-bromo-2-fluoroanilino)-6-metoxi-7-(1-metilpiperidin-4-ilmetoxi)quinazolina como monohidrato, composiciones farmacéuticas conteniéndolos y proceso de preparación
CL2008001282A1 (es) Composicion farmaceutica con actividad antimicrobiana que comprende un aminoacidos n halogenado y un agente antiinflamatorio; uso para prevenir o tratar una infeccion de tejidos, donde dicho tejido es ocular, nasal, seno nasal o dermico o una infeccion respiratoria.
CY1109393T1 (el) Η χρηση κιγχονης για την παρασκευη ενος φαρμακου που διεγειρει την αγγειογενεση
ATE424896T1 (de) Entpigmentisierende bzw. aufhellende kosmetikzusammensetzung, die mindestens ein oxazolin als wirkstoff umfasst
RU2007132165A (ru) Адапален для длительного лечения обыкновенных угрей

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120515